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Abstract
Background: The role of Th2 cells (producing interleukin (IL-)4, IL-5 and IL-13) in allergic asthma
is well-defined. A distinct proinflammatory T cell lineage has recently been identified, called Th17
cells, producing IL-17A, a cytokine that induces CXCL8 (IL-8) and recruits neutrophils.
Neutrophilic infiltration in the airways is prominent in severe asthma exacerbations and may
contribute to airway gland hypersecretion, bronchial hyper-reactivity and airway wall remodelling
in asthma.
Aim: to study the production of IL-17 in asthmatic airways at the mRNA level, and to correlate
this with IL-8 mRNA, neutrophilic inflammation and asthma severity.
Methods: We obtained airway cells by sputum induction from healthy individuals (n = 15) and
from asthmatic patients (n = 39). Neutrophils were counted on cytospins and IL-17A and IL-8
mRNA expression was quantified by real-time RT-PCR (n = 11 controls and 33 asthmatics).
Results:  Sputum IL-17A and IL-8 mRNA levels are significantly elevated in asthma patients
compared to healthy controls. IL-17 mRNA levels are significantly correlated with CD3γ mRNA
levels in asthmatic patients and mRNA levels of IL-17A and IL-8 correlated with each other and
with sputum neutrophil counts. High sputum IL-8 and IL-17A mRNA levels were also found in
moderate-to-severe (persistent) asthmatics on inhaled steroid treatment.
Conclusion: The data suggest that Th17 cell infiltration in asthmatic airways links T cell activity with
neutrophilic inflammation in asthma.
Background
Asthma is a T cell driven chronic inflammatory disorder of
the airways [1]. Both T helper (Th)2 and Th1 lym-
phocytes, play an important role in the pathophysiology
Published: 03 November 2006
Respiratory Research 2006, 7:135 doi:10.1186/1465-9921-7-135
Received: 24 January 2006
Accepted: 03 November 2006
This article is available from: http://respiratory-research.com/content/7/1/135
© 2006 Bullens et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Respiratory Research 2006, 7:135 http://respiratory-research.com/content/7/1/135
Page 2 of 9
(page number not for citation purposes)
of asthma [2-4]. Local overproduction of T helper (Th)2
cytokines (IL-4, IL-5, IL-9 and IL-13) by Th2 cells in the
asthmatic airways is well defined [4-6] and recent studies
indicate that Th1 cells, secreting IFN-γ, might cause severe
airway inflammation [7-9]. Recently, a separate T cell lin-
eage, called Th17 cells or inflammatory T cells, producing
IL-17A (or IL-17), has been identified [10,11]. Th17 cells
might potentially play an important role in the patho-
physiology of asthma. IL-17 is especially important for the
recruitment of neutrophils [12] and is expressed in bron-
chial biopsies, bronchoalveolar lavage fluid and sputum
of patients with asthma [13-15]. A role for IL-17 in murine
asthma models has also been described [16,17] and over-
expression of IL-17 in lung epithelium causes chemokine
production and leukocyte infiltration in vivo [10]. Neu-
trophils are especially prominent in acute, severe exacer-
bations of asthma [18,19]. Moreover, it has been
suggested that at least two inflammatory subtypes of
asthma exist: the eosinophilic and the non-eosinophilic
type [20]. The subgroup of patients with neutrophilic
asthma is characterized by poor response to corticoster-
oids [21]. Neutrophils potentially contribute to airway
gland hypersecretion, bronchial hyper-reactivity and to
airway wall remodelling [22,23] by producing matrix met-
alloproteinase-9 (MMP-9) observed in broncho-alveolar
lavage fluid from moderate-to-severe asthma patients
[24].
The mechanism of neutrophil recruitment in asthma is
still unclear, but several chemokines may have a role [25].
Among those, CXCL8 (IL-8), secreted by T lymphocytes,
epithelial cells, smooth muscle cells and macrophages
might especially be important, as CXCL8 (IL-8) is
increased in the airways of patients with asthma [26-29].
The non-invasive technique of sputum induction has
been developed to obtain viable cells from the lower air-
ways of asthma patients and healthy individuals [30] and
was later shown to be useful for studies on cytokine
mRNA expression by semi-quantitative [31] and quantita-
tive RT-PCR techniques. With this technique, mRNA lev-
els for cytokines and chemokines are normalized to a
house-keeping gene in order to correct for differences in
the cell number and amount of cDNA amongst the differ-
ent samples studied [32]. This method therefore avoids
some of the problems associated with protein measure-
ments in sputum samples. We have recently described the
use of this method for the quantification of Th1/Th2
cytokines at the mRNA level in induced sputum [9]. To
further study a potential role of Th17 cells in asthma, we
used the technique of induced sputum in combination
with quantitative real-time RT-PCR to quantify the expres-
sion of IL-17A and IL-8 mRNA in relation to each other,
to CD3γ mRNA as a quantification of T cells, and to the
neutrophilic inflammation in the airways of patients with
asthma.
Materials and methods
Subjects
This study was performed between September 2002 and
August 2004. Subjects have been extensively described
elsewhere [9]. In brief, thirty-nine asthmatic subjects (16
women, 23 men), not taking systemic steroids and 15 age-
matched healthy controls (8 women, 7 men) between 18
and 65 years were recruited. Asthma severity was scored
on the basis of the Global Initiative for Asthma (GINA)
criteria [33]. Mild intermittent (n = 11) and mild persist-
ent (n = 12) asthma patients were grouped as mild asth-
matics, and moderate (n = 8) and severe (n = 8)
asthmatics were grouped as moderate-to-severe asthmat-
ics. Asthmatic subjects were further subdivided into atop-
ics (n = 21) and non-atopics, (n = 17) based on detection
of specific IgE antibodies for house-dust-mite (n = 19),
pets (n = 12) and/or pollen (grass or tree) (n = 17) and on
a clinical history suggestive of allergic responses to those
allergens. No differences in FEV1% (Fishers' exact test: p =
0.48), asthma severity (GINA classification) (Fishers'
exact test: p = 0.49) and inhaled corticosteroids (ICS) use
(Fishers' exact test: p = 0.28) between the allergic and the
non-allergic asthmatics were found.
Patients were allowed to continue their usual treatment.
Thirteen patients regularly used ICS: <500 μg/day Beclom-
ethason Dipropionate (BDP) or equivalent (n = 1), 500–
1000 μg/day BDP or equivalent (n = 5) and >1000 μg/day
BDP or equivalent (n = 7); "non-users" either had never
used ICS or had not used them since at least 3 months. A
significantly larger proportion of patients with moderate-
to-severe asthma used ICS in comparison to patients with
mild asthma (Fishers' exact test: p < 0.0001).
Symptoms were measured using the asthma symptom
scores (ASS) [34] and the Asthma Control Questionnaire
developed by Juniper of which a validated Dutch transla-
tion is available [35]. Those scores significantly correlated
with each other [9]. The FEV1 was measured by means of
a spirometry. Bronchial hyperresponsiveness was deter-
mined by measuring the histamine concentration that
provoked a 20% decrease in FEV1 (PC20). Exhaled nitric
oxide (NO) was measured with an Ecophysics CLD 700
AL MED chemiluminescence analyser (n = 16)(Dürnten,
Switzerland).
Healthy controls had normal spirometry, no present clin-
ical symptoms of upper or lower airway disease, ASS of
zero and they did not use presently or in the past 5 years
any anti-asthma medication. Five of the 15 healthy con-
trols had allergic rhinoconjunctivitis and two others had a
history of oral allergy symptoms [9]. Sputum was not col-Respiratory Research 2006, 7:135 http://respiratory-research.com/content/7/1/135
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lected during the months April, May, June and July which
correspond to the tree-pollen and grass-pollen season in
Belgium.
The study was approved by the local ethical committee of
the Faculty of Medicine, Leuven.
Sputum induction and analysis
Sputum was induced by inhaling increasing concentra-
tions of hypertonic saline (3%, 4% and 5% for 7 minutes)
generated by a De Vilbiss Nebulizer (Ultra-NebTm 2000
model 200HI) after pre-treatment with 400 μg of inhaled
salbutamol (unless a fall in FEV1 of greater than 10%
occurred, in which case the procedure was stopped).
Sputum was processed by a modification of the technique
described by Pizzichini et al [36] which was recently pub-
lished [9]. In brief, all sputum plugs that appeared free of
salivary contamination were selected. Sputum was treated
by adding a volume of Hanks' Balanced Salt Solution con-
taining 0.1% dithiothreitol (Sigma, St. Louis, MO, USA)
and 3% Bovine Serum Albumin (Sigma). The cell pellet
was resuspended in 1000 μl RPMI 1640 (Bio Whittaker
Europe, Cambrex) containing 2 mM L-glutamine, penicil-
lin (100 U/ml), streptomycin (100 μg/ml) (Bio Whittaker
Europe) and 10% bovine calf serum (BCS) (Hyclone,
Logan, UT, USA). Sputum squamous cell percentage var-
ied between 0% and 35.6% (mean 6.6%). The cell suspen-
sion was adjusted to 1.0 × 106 cells/ml, and 50,000 cells
were put in a Shandon 3 Cytocentrifuge (Techgen, Zellik,
Belgium). Cytospins were air-dried and stained using May
Grünwald Giemsa. In each sample, 250 leukocytes were
counted and the percentage of each specific cell type was
determined.
Measuring cytokine mRNA
Cells were stocked on lysis buffer from the Qiagen Mini
Rneasy kit (Maryland, USA) at -20°C until use. RNA was
isolated from induced sputum of 33 patients and 11 con-
trol subjects with the Qiagen Mini Rneasy kit (Maryland,
USA). Both differential cell count and cytokine mRNA
were measured in 29 of the patients. RNA was transcribed
to cDNA with the Ready-to-go T-primed First Strand Kit
(Amersham Pharmacia biotech, Uppsala, Sweden). Real-
time quantitative PCR was performed for interleukin (IL)-
8, IL-17A, IL-5, CD3γ and β-actin in the ABI prism 7700
Sequence Detector System (Applied Biosystems, Foster
City, CA) as described [32]. cDNA plasmid standards,
consisting of purified plasmid DNA specific for each indi-
vidual target, were used to quantify the target gene in the
unknown samples, as described [32]. All results were nor-
malised to β-actin to compensate for differences in the
amount of cDNA. For each cytokine at least one primer or
probe spans an intron. The primer and probe sequences
for IL-17A and CD3γ were designed with Primer Express
(Applied Biosystems):
IL-17A FW 5'AATCTCCACCGCAATGAGGA3'
IL-17A RV 5'ACGTTCCCATCAGCGTTGA3'
IL-17A TP 5'FAM-CGGCACTTTGCCTCCCAGATCACA-
TAMRA3'.
CD3γ FW 5'TCATTGCTGGACAGGATGGA3'
CD3γ RV 5'GGGCTGGTAGAGCTGGTCATT3'
CD3γ TP 5'FAM-CGCCAGTCGAGAGCTTCAGACAAGC-
TAMRA3'
IL-8 primers and probe were a gift from Prof. Dr. G. Ver-
leden (division of Pneumology, UZ Gasthuisberg). The
primers and probes for IL-5 and IL-8 have been reported
[9,37]. All primers and probes were purchased from
Applied Biosystems or Eurogentec S.A.
Statistics
Statistical analyses were performed with GraphPad Prism
(GraphPad Software Inc., San Diego, USA) by using the
non-parametric Kruskall-Wallis, Mann-Whitney U test or
student-t test were appropriate. Variances were tested with
the F test and normality was analysed with the Kol-
mogorov Smirnov test. Correlation studies were per-
formed by Spearman non-parametric test. Contingency
tables were analysed by Fisher's exact test. A difference was
considered to be significant when p < 0.05.
Results
Sputum samples were obtained from 15 controls and 39
asthmatics. Sputum mRNA expression of IL-17A (figure
1A) and IL-8 (figure 1B) was significantly higher in asth-
matic patients in comparison to healthy controls.
Increased IL-17A mRNA and/or IL-8 mRNA levels could
discriminate asthma patients from the healthy control
group at a cut-off of 5 for IL-17A mRNA (p = 0.0006 by
Fisher's exact test) and at a cut-off of 30 for IL-8 mRNA (p
= 0.0009 by Fisher's exact test).
Asthma severity was evaluated on the basis of the revised
Global Initiative for Asthma (GINA) criteria [33]. When
compared to healthy control individuals, IL-17A and IL-8
mRNA levels in induced sputum were significantly higher
in mild asthmatics and in moderate-to-severe asthmatics
(figure 1A,B). IL-8 mRNA levels were higher in patients
with moderate-to-severe asthma than in patients with
mild asthma, whereas IL-17A mRNA levels were similarly
elevated in both subgroups (figure 1A,B). A significantly
higher proportion of patients with moderate-to-severeRespiratory Research 2006, 7:135 http://respiratory-research.com/content/7/1/135
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asthma then with mild asthma had very high levels of IL-
8 mRNA (above 50) and/or IL-17A mRNA values (above
50) (IL-8 mRNA: cut-off >50, p = 0.009 and IL-17A mRNA
cut-off >50: p = 0.03 by Fisher's exact test respectively).
Although patients treated with corticosteroids (open sym-
bols in figure 1B) tended to have higher levels of IL-8
mRNA in comparison to those that did not receive corti-
costeroids (closed symbols), the difference between those
two groups was not statistically significant. IL-17A and IL-
IL-17A and IL-8 mRNA levels in healthy controls and asthmatics Figure 1
IL-17A and IL-8 mRNA levels in healthy controls and asthmatics. RNA was isolated from induced sputum of healthy 
controls (n = 11) and asthmatic patients (n = 33) and real time RT-PCR was performed with β-actin, IL-17A and IL-8 specific 
primers and with VIC-(β-actin) or FAM-(IL-17A, IL-8) labelled specific probes. Results were quantified by the use of a cDNA 
plasmid-standard and expressed as the ratio of cDNA copy numbers for IL-17A (A-C) or IL-8 (B-D) divided by the cDNA copy 
numbers for β-actin multiplied by 104 (A-C) or 101 (B-D). Patients were divided in subgroups according to asthma severity fol-
lowing the reviewed GINA criteria [33] (A, B) and allergic state (allergic state was not known in one patient and two patients 
with only specific IgE for grass pollen were excluded for the comparison of allergic to non-allergic asthma) (C, D). Open sym-
bols represent patients treated with corticosteroids, closed symbols represent patients without corticosteroid-treatment. 
Comparisons were performed using the Kruskall-Wallis and Mann-Whitney-U test. The median is indicated with a horizontal 
line. * = p < 0.05, ** = p < 0.01, *** = p < 0.001 and ns = not significant.Respiratory Research 2006, 7:135 http://respiratory-research.com/content/7/1/135
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8 mRNA expression were similarly distributed in non-
allergic and allergic patients (Figure 1C,D). As shown in
figure 2A, the IL-17A and IL-8 mRNA levels correlated sig-
nificantly with each other, which was expected as IL-17A
has been shown to induce IL-8 release [25]. However, and
to our surprise, the IL-17A mRNA levels also correlated
significantly with the IL-5 mRNA levels (figure 2B). Data
for IL-5 were separately reported [9].
We found no correlation between the asthma symptom
control on the basis of the scoring systems and the IL-17A
and/or IL-8 mRNA levels, whether studied in all patients
CD3γ mRNA levels in healthy controls and asthmatics, correlations between IL-17A and CD3γ and between IL-17A other  cytokine/chemokine mRNA levels Figure 2
CD3γ mRNA levels in healthy controls and asthmatics, correlations between IL-17A and CD3γ and between 
IL-17A other cytokine/chemokine mRNA levels. CD3γ, IL-8, IL-17A and IL-5 mRNA levels in induced sputum of asth-
matic patients were quantified as explained in figure 1 using IL-8, IL-17A and IL-5 specific primers and VIC-(β-actin) or FAM-(IL-
8, IL-17A, IL-5) labeled specific probes. Asthma severity was determined as in figure 1A. Open symbols represent patients 
treated with corticosteroids, closed symbols represent patients without corticosteroid-treatment. Comparisons were per-
formed using the Kruskall-Wallis test and Dunn's post test (C). Correlations were studied by Spearman non-parametric test 
(A-B, D). The median is indicated with a horizontal line. * = p < 0.05, ** = p < 0.01, *** = p < 0.001, and ns = not significant.Respiratory Research 2006, 7:135 http://respiratory-research.com/content/7/1/135
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or in the steroid-naive patients only (data not shown).
NO in exhaled air [38] and airway hyper-responsiveness
measured by histamine provocation (PC20) did not cor-
relate with either IL-17A or IL-8 mRNA, whether steroid
naïve and steroid treated patients were studied separately
in two subgroups or as one group (data not shown).
Levels of CD3γ mRNA, reflecting infiltrating T cells are
low in controls and significantly increased in moderate-
to-severe asthmatics (figure 2C). In the asthmatic patient
group in total (r = 0.5, p = 0.0079) and in the subgroup of
moderate to severe asthmatics (r = 0.8, p = 0.003), a sig-
nificant positive correlation between CD3γ mRNA and IL-
17A mRNA levels was observed (figure 2D). Compared to
mild asthmatics, increased sputum neutrophil counts
were observed amongst patients with moderate-to-severe
asthma (figure 3A, open symbols represent patients on
inhaled steroids). Neutrophil counts were significantly
higher in steroid-treated than in steroid-naïve patients (p
< 0.05, data not shown). As shown in figure 3B–C, both
IL-17A and IL-8 mRNA levels significantly correlated with
the sputum neutrophil (p = 0.02, r = 0.4 and p = 0.0002,
r = 0.7 respectively) but not eosinophil (p = 0.4, r = 0.2
and p = 0.7, r = -0.09 respectively)(data not shown) count
in the patient group. In the subgroup of steroid-naïve
patients, IL-8 mRNA levels also significantly correlated
with the sputum neutrophil count (p = 0.003, r = 0.7) but
IL-17A mRNA levels did not (p = 0.2, r = 0.3).
We found no correlation between the sputum neutrophil
count and the ASS or the ACQ (data not shown). Allergic
and non-allergic asthmatics had comparable sputum neu-
trophil counts (data not shown).
Discussion
In this study we have investigated local IL-17A, IL-8 and
CD3γ mRNA expression in relation to the cellular infiltra-
tion in the airway lumen from asthmatic patients and
healthy controls as assessed by sputum induction. We
found higher levels of both IL-17A and CD3γ (reflecting T
cell infiltration) mRNA in asthmatic patients when com-
pared to healthy controls. Levels of CD3γ were highest in
the moderate and severe patient group and correlated in
that group with IL-17A mRNA expression, suggesting
increased levels of the newly described Th17 cell lineage
[10,11]. This correlation was absent in healthy controls
and even tended to be negative, showing that T cells in the
airways of healthy individuals do not belong to the Th17
cell lineage. Moreover, all healthy individuals had low to
undetectable IL-17A and IL-8 mRNA levels in their spu-
tum cells, which makes increased IL-17A or IL-8 mRNA
levels potentially useful as a diagnostic aid in asthma. We
also found in the asthmatic population that both IL-17A
and IL-8 mRNA levels correlate significantly with the spu-
tum neutrophil count. This correlation was recently also
observed by other authors at the protein level [14]. A sig-
nificant correlation between IL-8 mRNA and IL-17A
mRNA on the one hand and with neutrophils on the other
hand suggests (although it does not provide proof for)
cause-effect relationship. Human bronchial epithelial
cells, fibroblasts and airway smooth muscle cells recruit
neutrophils into the airways by the release of CXCL8 (IL-
8) and/or other chemokines (such as granulocyte chemo-
tactic protein-2 and growth-related oncogene(GRO)-α)
upon stimulation by IL-17[13,39,40]. Until now, no other
cellular source for IL-17 besides T cells has been identi-
fied. IL-17 in the airways is most likely produced by a T
helper lineage called 'inflammatory T cells' or Th17 cells
[10,11] and this could represent the link between T cell
inflammation and granulocytic influx. The study of those
'inflammatory T cells' might become of specific interest in
order to unravel differences between eosinophilic and
non-eosinophilic asthma phenotypes [20,41]. Somewhat
surprising, the levels of IL-17 and IL-5 mRNA positively
correlated with each other. This suggests that the inflam-
matory cell type and the Th2 type are both recruited in
inflamed airways. Another explanation could be that both
cytokines can be secreted by the same cell type. This is the
aim of further study.
In order to study whether different subgroups of asthma
patients could have differences in the expression of spu-
tum IL-17A or IL-8 mRNA levels, we compared allergic to
non-allergic asthmatics and mild to moderate/severe asth-
matics. Allergic and non-allergic patients had similar IL-
17A and IL-8 mRNA levels, but differences in the IL-17A
and IL-8 mRNA expression level depending on disease
severity could be found. High IL-17A and/or IL-8 mRNA
levels were always found in patients with moderate/severe
asthma while only approximately half of the mild asth-
matics had increased IL-17A and/or IL-8 mRNA levels in
their sputum. In accordance with this, the highest sputum
neutrophil count was also found in the subgroup of
patients with moderate-to-severe asthma, as also observed
by other authors [14,25]. Most of the moderate-to-severe
asthmatic patients were treated by inhaled corticosteroids.
Our findings are consistent with recent observations sug-
gesting that corticosteroid treatment can increase the
number of neutrophils in endoscopic biopsy specimens
from patients with moderate-to-severe asthma [42].
Increased presence of neutrophils as observed in patients
treated with inhaled corticosteroids might thus reflect
enhanced neutrophil survival upon treatment with ster-
oids, rather than higher disease severity. This might be due
to the fact that corticosteroids protect neutrophils against
apoptosis while they induce eosinophil apoptosis [43].
Another potential explanation is that neutrophil recruit-
ing Th17 cells or cytokines are steroid resistant. A signifi-
cant limitation is that it is clinically challenging to
correlate sputum IL-17A mRNA expression with neu-Respiratory Research 2006, 7:135 http://respiratory-research.com/content/7/1/135
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Sputum neutrophil counts in healthy controls and asthma patients and correlation of IL-17A and IL-8 mRNA levels with the  neutrophil count in asthmatics Figure 3
Sputum neutrophil counts in healthy controls and asthma patients and correlation of IL-17A and IL-8 mRNA 
levels with the neutrophil count in asthmatics. Cytospins of induced sputum of healthy controls (n = 11) and asthmatic 
patients (n = 32) were stained with May Grünwald Giemsa. Neutrophils are counted as percentage of the leukocytes. IL-17A 
and IL-8 mRNA levels in induced sputum of asthmatic patients (n = 27) were determined as explained in figure 1 and 2. Open 
symbols represent patients treated with corticosteroids, closed symbols represent patients without corticosteroid-treatment. 
The mean is indicated with a horizontal line. Differences are studied by student t-test (A) and correlation was studied by Spear-
man non-parametric test (B-C). * = p < 0.05, ** = p < 0.01 and *** = p < 0.001.Respiratory Research 2006, 7:135 http://respiratory-research.com/content/7/1/135
Page 8 of 9
(page number not for citation purposes)
trophil influx (and disease severity) while excluding the
confounding variable of inhaled corticosteroid use, which
could independently contribute to neutrophil influx. To
resolve this discussion, IL-17A and IL-8 mRNA expression
as well as neutrophil influx should now be studied before
and after the introduction of inhaled steroids. The persist-
ence of IL-17 and of neutrophils despite steroid treatment
is indeed of potential prognostic significance as neu-
trophils can contribute to the phenomenon of airway
remodeling and irreversible airway obstruction [13,22].
In conclusion our findings suggest Th17 T cell infiltration
and ensuring production of IL-17A mRNA in asthmatic
airways in parallel with increased IL-8 mRNA levels as the
plausible cause of neutrophilic infiltration. High IL-17A
and/or IL-8 mRNA levels were found in patients with
moderate-to-severe asthma, even if those patients were
treated with corticosteroids. In those patients, high IL-17A
levels correlate with CD3γ expression, suggesting that a
substantial proportion of airway T cells are Th17 cells.
These might be responsible for neutrophil recruitment,
with IL-8 as an important intermediate chemokine.
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